Crestchem Limited successfully concluded its Board of Directors meeting on March 31, 2026, addressing critical business matters including performance review, strategic planning, and key personnel appointments. The meeting, which commenced at 12:15 PM and concluded at 1:30 PM at the company's corporate office in Ahmedabad, covered comprehensive agenda items as previously communicated to BSE Limited.

Performance Review and Strategic Planning

The board conducted an extensive review of the company's performance during 2025-26, evaluating operational achievements against prevailing market conditions. Directors discussed suitable measures adopted by the company to navigate current business challenges and outlined strategic initiatives for sustainable growth.

The Chairman & Managing Director presented detailed plans for 2026-27, specifically addressing how the company will overcome challenges posed by global geopolitical tensions, including the ongoing conflicts involving USA, Israel, and Iran that have impacted worldwide business operations.

Key Personnel Appointments and Reappointments

The board approved significant personnel decisions that will shape the company's leadership structure for the coming years. These appointments reflect the company's commitment to strengthening its management team and operational capabilities.

Governance and Compliance Matters

Shri Nirmit D. Patel's reappointment as Executive Director, classified as Key Managerial Personnel (KMP) and relative of Dipak Narendraprasad Patel, received approval from both the Audit Committee and Remuneration Committee. The appointment remains subject to member approval in the upcoming Annual General Meeting.

Smt. Tansi Nirmit Patel's appointment as Accounts & Secretarial Assistant represents a strategic addition to the company's administrative team. As a Non-KMP relative of both Dipak Narendraprasad Patel and Nirmit Dipak Patel, she will receive a fixed monthly remuneration of Rs. 30,000 along with eligibility for performance incentives as per company policy applicable to all employees.

Company Information and Regulatory Compliance

Crestchem Limited, incorporated under CIN L24100GJ1991PLC015530, operates from its corporate office at Central Business Space, Ashram Road, Ahmedabad. Company Secretary and Compliance Officer Nitin S. Shah (ACS-7088) has communicated the meeting outcomes to BSE Limited under Regulation 30, ensuring full regulatory compliance and transparency for stakeholders.

Crestchem has released its unaudited standalone financial results for the quarter and half-year ended September 30, 2025, revealing a mixed financial performance. The company's Board of Directors approved these results at a meeting held on November 12, 2025.

Financial Highlights

Key Points

• Revenue: The company reported revenue from operations of ₹30.75 for the quarter ended September 30, 2025.
• Profit Decline: Crestchem experienced a significant decrease in profit after tax for the half-year period, dropping from ₹365.68 in the previous year to ₹99.70.
• Asset Growth: Despite the profit decline, the company's total assets increased to ₹1,354.86, up from ₹1,054.49 in the previous period, indicating potential investments or acquisitions.
• Improved Liquidity: Cash and cash equivalents saw a notable increase, rising to ₹104.60 from ₹73.15, potentially strengthening the company's short-term financial position.

Corporate Governance

In line with regulatory requirements, Crestchem has implemented measures to ensure compliance with insider trading regulations:

• The trading window for company securities remains closed from July 1, 2025, until 48 hours after the public announcement of the financial results.
• This closure applies to directors, officers, key managerial personnel, and designated persons as defined under the company's internal code for prohibition of insider trading.

The financial results were approved at a board meeting that commenced at 12:30 PM and concluded at 4:00 PM on November 12, 2025. The company has submitted these results to the BSE Limited in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Investors and stakeholders should note that these are unaudited results and may be subject to review.